Withdrawn prior to enrolment after review of updated safety data
Summary
This study aims to evaluate how well the effectiveness of the medicine Tazemetostat works in adults with relapsed/refractory follicular lymphoma, a slow-growing type of blood cancer that affects a kind of white blood cell called lymphocytes.
All participants will receive Tazemetostat as prescribed by their doctor in the routine clinical practice.
The study will observe how participants respond to the treatment, how long the response lasts, and monitor safety, side effects and how well participants tolerate the treatment.
Protocol Amendment History
3 changes
criticalTrial status changed: Not Yet Recruiting → Withdrawn2026-04-30
criticalReason stopped changed: — → Withdrawn prior to enrolment after review of updated safety data2026-04-30